This post from the Pharmalot blog indicates that all the perceived negatives that Dendreon's Provenge might be facing do NOT seem to be effecting the drug's initial acceptance. In a quick survey of 25% of the sites expected to prescribe Provenge - more than half plan to prescribe next month.
Further, any doubts about reimbursement aren't effecting the prescribing physcians' intention to prescribe to additional patients. In fact, 8 of the 13 centers have a wait list. A high penetration rate is therefore expected in defiance of naysayers predictions.
Posted by Bruce Lehr July 26th 2010.